By Lilian Massihi, MD, Board-Certified Family Medicine, Advanced BHRT Certification
It started as a small thing. A dryness that was not there a year ago. A sting in the shower. A burn after sex that lasted into the next day and made you quietly decide to skip the next one.
You brought it up once. Probably at the end of a visit, in the last two minutes, coat already on. You were told to try a lubricant, and the conversation moved on to something else.
So you tried one. Then a different one. Then the coconut oil, the vitamin E capsules, the serum with the hyaluronic acid and four thousand good reviews. Some of it made the next hour easier. None of it made the problem stop coming back.
Here is what those two minutes left out, and it is the part that matters. Almost every other symptom of this transition eventually burns itself out. Hot flashes end. Night sweats end. This one is the exception. Left alone it does not level off, it keeps going. And it was never only a vaginal symptom, which is why the urinary urgency and the infections that will not stay away often show up in the same year and get handled as a separate problem by a separate doctor.
What is actually happening to the tissue
The condition has a name, and the name was changed on purpose. In 2014 the International Society for the Study of Women’s Sexual Health and the North American Menopause Society, the professional body for menopause clinicians in the United States and Canada, held a joint consensus conference and replaced the old term vulvovaginal atrophy with genitourinary syndrome of menopause. Their definition is worth reading slowly: a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids, involving changes to the labia, the clitoris, the vestibule, the vagina, the urethra and the bladder.
Read that list again. The urethra and the bladder are in it. One hormonal change, one continuous stretch of tissue, two specialties that rarely compare notes.
The mechanism is unglamorous. The tissue of the vulva, vagina and lower urinary tract is unusually responsive to estrogen. As estradiol falls across the transition, that tissue becomes thinner and less elastic, blood flow to it drops, it produces less of its own moisture, and the acidity that kept its bacterial balance in check shifts. A review in Menopause, the peer-reviewed journal of that same professional society, describes the result plainly: symptoms arising from diminished estrogenic stimulation of the vulvovaginal and lower urinary tract, ranging from dryness, burning and irritation to pain with sex, urinary urgency, pain on urination and recurrent urinary tract infection.
That is why a product applied at the moment of discomfort can help the moment and change nothing underneath it. It is working on the symptom. The tissue is responding to a hormone that is no longer there.
Why this one does not fade on its own
This is the sentence nobody says out loud. The same review states that these symptoms are typically progressive and unlikely to resolve spontaneously. Not seasonal. Not a phase to outlast. Progressive.
It is also not rare. The 2020 position statement of the North American Menopause Society puts the figure at roughly 27 to 84 percent of postmenopausal women, a range that wide because the condition is counted differently depending on who is asking and how. The statement then says the thing that should be the headline: genitourinary syndrome of menopause is likely underdiagnosed and undertreated, and in most cases the symptoms can be effectively managed.
Why underdiagnosed, when it affects this many women? An overview in the American Journal of Obstetrics and Gynecology, a peer-reviewed journal in women’s health, is blunt about the reason: it affects more than half of postmenopausal women and is greatly underdiagnosed because of embarrassment and the sensitive nature of discussing the symptoms. Nobody is hiding this condition from you. It is being skipped in the room, by both people in it.
The scale of the gap shows up in an unexpected place. In announcing its recent labeling changes, the US Food and Drug Administration noted that in 2020 about 41 million American women were between 45 and 64 years old, while only about 2 million women aged 46 to 65 received a prescription for hormone therapy of any kind. That figure covers all hormone therapy, not this symptom alone, but the shape of it is the point.
What the trials show, including the one that did not go the way we expected
If a practice only tells you the studies that flatter what it offers, you are reading marketing. So here is the trial that complicates this.
In 2018, JAMA Internal Medicine, a peer-reviewed journal of the American Medical Association, published a 302 woman randomized trial that compared a 10 microgram vaginal estradiol tablet against an over the counter vaginal moisturizer, each against placebo, over 12 weeks. The women averaged 61 years old, and the most common complaint was pain with penetration. Over 12 weeks the severity of each woman’s most bothersome symptom fell by 1.4 points on a 0 to 3 scale in the estradiol group, 1.2 in the moisturizer group, and 1.3 in the placebo group. The differences were not statistically significant. The authors’ conclusion was that neither the prescribed tablet nor the moisturizer provided additional benefit over placebo.
Take that seriously. It is also worth noticing what the placebo was: a tablet placed on a schedule plus a gel used three times a week. Every arm of that trial involved treating the tissue consistently for twelve weeks, and every arm improved by roughly the same amount. That is a finding about these two specific products against that comparison, not a finding that nothing helps.
The wider evidence base sits above it and is itself imperfect. The Cochrane Collaboration, the international group that grades medical evidence for a living, pooled 30 randomized trials covering 6,235 women on estrogen applied vaginally. Women using an estrogen ring reported improvement far more often than women using placebo, an odds ratio of 12.67, but that comparison rested on a single trial of 67 women with a confidence interval running from 3.23 to 49.66. The reviewers graded the overall evidence low to moderate quality, limited by poorly reported study methods and imprecise estimates. They also found more evidence of increased endometrial thickness with cream than with the ring across two trials, which they attributed to the higher doses used in cream rather than to the route itself.
What an honest physician does with that is tell you both halves. The direction of the evidence supports treating the tissue rather than the moment. The strength of that evidence does not support anyone promising you an outcome, and a number resting on 67 women is a signal, not a guarantee.
The procedure the evidence does not support
Into a field that confusing came a device, and it is now sold widely as a way to restore the tissue with a laser. It is worth knowing what happened when somebody finally tested it properly.
In 2021, JAMA, the peer-reviewed journal of the American Medical Association, published a double blind randomized trial of fractional carbon dioxide laser against a sham procedure in 85 postmenopausal women with symptoms severe enough that they had sought treatment. Three sessions, then twelve months of follow up. There was no significant difference between the laser and the sham in symptom severity, in quality of life, in the examination score of vaginal health, or in what the tissue looked like under a microscope. Side effects were about as common in both groups.
A sham-controlled trial is the only design that separates a treatment from the experience of being treated, and for years this category grew without one. That is not a claim about any particular clinic. It is a statement about what was known at the time the marketing was written.
The urinary half that gets handled separately
If you have been through two or three courses of antibiotics in a year and nobody connected that to the dryness, this section is for you.
Recurrent urinary tract infection sits inside the definition of this condition, not beside it. In a randomized trial published in Female Pelvic Medicine and Reconstructive Surgery, a peer-reviewed journal of urogynecology, 35 postmenopausal women with a documented history of recurrent infection were assigned to vaginal estrogen, given as a ring or a cream, or to a placebo cream. At six months, 11 of 18 women using estrogen had an infection, compared with 16 of 17 in the placebo group.
Thirty-five women is a small trial and the result should be held lightly. But it points at the same mechanism as everything above, and it is the reason this belongs in one conversation with one physician rather than being split between the practice that treats your infections and the practice that treats your transition.
The label changed in February. The fear did not.
For twenty years the question that ended this conversation was cancer, and the fear was not invented. It came from the 2002 Women’s Health Initiative, and the detail that was lost in the headlines is the one that matters most: that study used conjugated equine estrogens with a synthetic progestin, in women who were on average more than a decade past menopause. That is a different drug and a different patient from a woman in her early fifties being prescribed estradiol. We will not soften that distinction, because it is the whole distinction.
The regulator has now moved. On February 12, 2026, the FDA approved labeling changes to the first six menopausal hormone therapy products, removing the risk statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning, the agency’s most prominent safety warning. The FDA initiated that review in November 2025, and the six products span all four categories of menopausal hormone therapy, including topical vaginal estrogen therapy. One warning was deliberately kept: the endometrial cancer warning on systemic estrogen taken alone by a woman who still has her uterus, which is exactly why progesterone belongs in the conversation whenever estrogen is systemic.
None of that means the decision is automatic or that it is the same decision for every woman. It means the paperwork finally caught up with the evidence, and that the sentence you were handed in 2009 is no longer the sentence on the box. Whether any of this suits you is a judgment made with your own history in front of us, personal and family both, which is the part a label can never decide. If the cancer question is the one holding you still, we have written about it at more length in what the science actually says about hormone therapy and safety.
What is worth measuring, and what is not
You may be expecting a panel. There is not one. The diagnosis here is clinical, which the Menopause review states directly, and no blood test defines this condition or rules it out.
What changes the outcome is a conversation specific enough to tell these causes apart, and an examination. Which labs are worth drawing, and when, is a judgment made with your chart open rather than a standing protocol applied to everyone, because a woman with recurrent infections, a woman with a vulvar skin change and a woman whose only symptom arrived with her last period are not the same patient.
This also happens to be a condition the Menopause review notes telemedicine can reasonably serve, from the first conversation through follow up, which matters in a state where the nearest physician who will take this seriously may be two hours away. Hormone optimization is the practice’s whole subject, not a line item on a longer menu.
What not to assume is hormonal
Claiming this entire territory would be the easy move and it would be wrong. Several of these causes are not hormonal, and they are not managed the same way.
- Vulvar skin conditions. Lichen sclerosus and related conditions can cause burning, splitting and architectural change, and they need a diagnosis and a different treatment. Persistent pale, thickened or scarred vulvar skin is a reason to be examined, not a reason to buy a stronger moisturizer.
- Contact irritation from the products bought for relief. Fragranced washes, warming or flavoured lubricants and heavily preserved serums can keep inflamed tissue inflamed.
- Infection. Discharge, odour or itching with a new pattern deserves to be tested rather than assumed.
- Medications that lower estrogen or dry mucous membranes. Aromatase inhibitors and tamoxifen do the first; some antihistamines and other common drugs do the second.
- Other low estrogen states, including the months after childbirth and while breastfeeding, and treatment that affects ovarian function.
And one hard line, because this is the symptom women most often sit on: bleeding after sex, or any bleeding at all after menopause, is evaluated promptly. It is usually not cancer. It is never something to manage at home.
If you have had breast cancer, this conversation is not closed to you, but it is not ours to settle alone. The options, including local ones, are weighed together with your oncology team, and systemic hormone therapy remains a separate question with its own answer.
Frequently Asked Questions
Is this really just a lubricant problem?
A lubricant solves friction in the moment, and for some women that is genuinely enough. What it does not do is change the tissue, and the published descriptions of this condition are consistent that the underlying change is progressive and unlikely to resolve on its own. If you have been managing it with products for a year or more and the baseline keeps moving in the wrong direction, that is the answer to this question.
Is vaginal estrogen the same thing as taking hormones?
It is a different route and a different product category. The FDA treated it as its own category in the February 2026 labeling action, listing topical vaginal estrogen therapy separately from systemic estrogen, systemic combination therapy and progestogen. Whether it is appropriate for you is a decision made with your history, not a decision the category makes for you.
Will it get better if I wait?
Probably not, and that is the honest difference between this symptom and the others. Hot flashes and night sweats generally run a course and end. The published reviews describe these genitourinary symptoms as typically progressive and unlikely to resolve spontaneously, which is why waiting is itself a decision.
Does the laser work?
The strongest test of it so far, the sham-controlled trial in JAMA described above, found no significant benefit over a sham procedure at twelve months on symptoms, quality of life, examination score or tissue appearance. That is one trial of 85 women, and it is also the best designed trial in the category. Anyone offering it should be able to tell you that trial exists.
Can this be handled over telehealth?
Often, yes, and the published reviews name telemedicine as a reasonable route for diagnosis, starting treatment and follow up for this condition. Some presentations need an examination, and we will say so when that is the case rather than working around it. AllureMD sees patients across Mississippi by telehealth, and the symptoms described here are part of the ordinary work of perimenopause and menopause care. If low desire is the part that bothers you most, the estrogen side of this is addressed first for a reason, which we explain in our post on the symptom most clinics never test for.
AllureMD is a physician-led hormone optimization practice in Madison, Mississippi. This is the symptom most often answered with a product from a shelf and the one least likely to improve while it is being managed that way, which is why it is worth saying out loud in a visit that has time for it. Lilian Massihi, MD evaluates each patient’s complete hormonal picture before making any recommendation. To schedule your consultation, book a complimentary discovery call.
About the Author
Lilian Massihi, MD is a board-certified family medicine physician and hormone optimization specialist who completed her undergraduate education at UCLA, earned her medical degree at the University of Poznań, and finished her residency at the University of Mississippi Medical Center. For more than five years, she practiced as a hospitalist, treating patients in the late stages of cardiovascular disease, cognitive decline, and severe osteoporosis. She kept asking the same question: what would have been different if someone had intervened sooner? That question led her to bioidentical hormone therapy, where a rigorous review of the evidence changed the direction of her career. She founded AllureMD in Madison, Mississippi to practice the kind of medicine she had come to believe in: treating the entire hormonal system, titrating to how patients actually feel, with a physician leading every decision.